WAYNE, N.J., March 14, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception. With this approval, Natazia is the first and only oral contraceptive indicated for the treatment of HMB.
For complete Article : Click Here (ref : drugs.com)
For complete Article : Click Here (ref : drugs.com)
No comments:
Post a Comment
Ask your doubts / point out towards any error / show appreciation / explain anything you wish to.